Welcome to LookChem.com Sign In|Join Free
  • or
PD 166326 is a chemical with a specific purpose. Lookchem provides you with multiple data and supplier information of this chemical.

185039-91-2

Post Buying Request

185039-91-2 Suppliers

Recommended suppliers

  • Product
  • FOB Price
  • Min.Order
  • Supply Ability
  • Supplier
  • Contact Supplier

185039-91-2 Usage

Biological Activity

pd 166326 is a receptor tyrosine kinase inhibitor.receptor tyrosine kinases are the high-affinity cell surface receptors for many growth factors, cytokines, as well as hormones. they have been shown not only to be critical regulators of normal cellular processes but also to have a key role in the development of many types of cancer.

in vitro

pd 166326 was identified as a pyridopyrimidine-type inhibitor of receptor tyrosine kinases inhibiting c-abl and bcr/abl-dependent cell growth. in addition, pd 166326 could also potently inhibit c-src. moreover, pd166326 was found to be superior to imatinib mesylate in inhibiting the constitutive tyrosine phosphorylation of numerous leukemia-cell proteins, such as the src family member lyn [1, 2].

in vivo

in mice with the cml-like disease, pd166326 could rapidly inhibit bcr/abl kinase activity after a single po dose and showed great antileukemic activity. it was found that 70% of pd166326-treated mice achieved a white blood cell count less than 20.0 × 109/l at necropsy, compared with 8% of imatinib mesylate–treated animals. furthermore, 2/3 of pd166326-treated mice had complete resolution of splenomegaly, compared with none of the imatinib mesylate–treated animals. in addition, pd166326 could also prolong the survival of mice with imatinib mesylate–resistant cml induced by the bcr/abl mutants of p210/h396p and p210/m351t [2].

IC 50

8 nm for c-abl

references

[1] wisniewski, d. ,lambek, c.l.,liu, c., et al. characterization of potent inhibitors of the bcr-abl and the c-kit receptor tyrosine kinases. cancer research 62(15), 4244-4255 (2002).[2] wolff, n. c.,veach, d.r.,tong, w.p., et al. pd166326, a novel tyrosine kinase inhibitor, has greater antileukemic activity than imatinib mesylate in a murine model of chronic myeloid leukemia. blood 105(10), 3995-4003 (2005).

Check Digit Verification of cas no

The CAS Registry Mumber 185039-91-2 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 1,8,5,0,3 and 9 respectively; the second part has 2 digits, 9 and 1 respectively.
Calculate Digit Verification of CAS Registry Number 185039-91:
(8*1)+(7*8)+(6*5)+(5*0)+(4*3)+(3*9)+(2*9)+(1*1)=152
152 % 10 = 2
So 185039-91-2 is a valid CAS Registry Number.

185039-91-2SDS

SAFETY DATA SHEETS

According to Globally Harmonized System of Classification and Labelling of Chemicals (GHS) - Sixth revised edition

Version: 1.0

Creation Date: Aug 16, 2017

Revision Date: Aug 16, 2017

1.Identification

1.1 GHS Product identifier

Product name PD 166326

1.2 Other means of identification

Product number -
Other names -

1.3 Recommended use of the chemical and restrictions on use

Identified uses For industry use only.
Uses advised against no data available

1.4 Supplier's details

1.5 Emergency phone number

Emergency phone number -
Service hours Monday to Friday, 9am-5pm (Standard time zone: UTC/GMT +8 hours).

More Details:185039-91-2 SDS

185039-91-2Upstream product

185039-91-2Downstream Products

185039-91-2Relevant academic research and scientific papers

2-Substituted aminopyrido[2,3-d]pyrimidin-7(8H)-ones. Structure-activity relationships against selected tyrosine kinases and in vitro and in vivo anticancer activity

Klutchko, Sylvester R.,Hamby, James M.,Boschelli, Diane H.,Wu, Zhipei,Kraker, Alan J.,Amar, Aneesa M.,Hartl, Brian G.,Shen, Cynthia,Klohs, Wayne D.,Steinkampf, Randall W.,Driscoll, Denise L.,Nelson, James M.,Elliott, William L.,Roberts, Billy J.,Stoner, Chad L.,Vincent, Patrick W.,Dykes, Donald J.,Panek, Robert L.,Lu, Gina H.,Major, Terry C.,Dahring, Tawny K.,Hallak, Hussein,Bradford, Laura A.,Showalter, H. D. Hollis,Doherty, Annette M.

, p. 3276 - 3292 (2007/10/03)

While engaged in therapeutic intervention against a number of proliferative diseases, we have discovered the 2-aminopyrido[2,3- d]pyrimidin-7(8H)-ones as a novel class of potent, broadly active tyrosine kinase (TK) inhibitors. An efficient route was devel

Post a RFQ

Enter 15 to 2000 letters.Word count: 0 letters

Attach files(File Format: Jpeg, Jpg, Gif, Png, PDF, PPT, Zip, Rar,Word or Excel Maximum File Size: 3MB)

1 Customer Service

What can I do for you?
Get Best Price

Get Best Price for 185039-91-2